OHE Consulting makes the expertise of the team at the Office of Health Economics available to organisations in all sectors – public, private and voluntary. The consultancy has the knowledge and skills to address a wide range of issues in health care and pharmaceutical policy, economics and statistics.
Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances. In a recent article in the British Journal of Clinical Pharmacology, Prof Adrian Towse examines the issues from a UK perspective. Managing and containing costs in the NHS is a perennial challenge. Far less clear is how to accomplish this while still ensuring sufficient incentives for timely access to new medical therapies, particularly new medicines.
Since 2007, new medications may be paid for by the statutory health insurance funds (GKV) in Germany only if they are cost-effective. Willingness-to-pay analyses can be essential background for decisions about the pricing and reimbursement of prescription medicines.
Jon Sussex, Deputy Director of the OHE, researches incentives and competition in UK health services. In July, he presented findings on ‘Payment by Results’ to the Health and Social Care Conference held by the Association of Chief Executives of Voluntary Organisations.